Monday morning started rough for U.S. markets, with futures pointing to a painful open. Dow futures dropped more than 300 points before the bell, setting a decidedly bearish tone for the week ahead.

Biotech Takes a Hit

Exelixis Inc. (EXEL) led the decliners after delivering preliminary financial results that clearly didn't thrill investors. The biotech company reported preliminary 2025 U.S. net product revenue of $2.123 billion and projected 2026 net product revenue between $2.325 billion and $2.425 billion. Whatever Wall Street was hoping for, this apparently wasn't it. Shares tumbled 4.6% to $42.01 in pre-market action.

Financial Sector Bloodbath

The financial sector bore the brunt of Monday's pre-market pain. Synchrony Financial (SYF) got hammered worst of all, plunging 9.5% to $78.61. Capital One Financial Corp (COF) wasn't far behind, dropping 8.4% to $228.35, while Bread Financial Holdings Inc (BFH) tumbled 8.3% to $73.72.

American Express Co (AXP) declined 5% to $357.00, and Citigroup Inc (C) fell 4% to $116.50. Citigroup is scheduled to release its fourth-quarter earnings results before the opening bell on Wednesday, January 14, which might explain some of the jitters.

Other Notable Decliners

Stoke Therapeutics Inc (STOK) dropped 8.7% to $30.00 after announcing updates to enrollment timelines and the Phase 3 data readout from its EMPEROR study of zorevunersen for treating Dravet syndrome. Clinical trial delays rarely inspire confidence.

Himalaya Shipping Ltd (HSHP) dipped 5.7% to $8.72, while Mesoblast Ltd (MESO) fell 5.1% to $19.90. The Mesoblast decline is particularly interesting given that shares had gained more than 5% on Friday following the company's report of year-over-year growth in December Ryoncil sales. Apparently, that enthusiasm didn't survive the weekend.

Rounding out the losers: Lumentum Holdings Inc (LITE) fell 4.7% to $335.00, and WPP PLC (WPP) declined 4.5% to $22.63.

With financial stocks leading the retreat and futures pointing south, Monday shaped up to be one of those days where investors might want to keep the coffee strong and expectations modest.